Whalesbook
Norges Bank Ki Entry: Yeh Kyun Bada Deal Hai?
Norges Bank ka yeh investment Emcure ke future par ek bada bharosa dikhata hai. Ek major global investor se itna bada stake khareedna company ke liye achhi khabar hai.
Stock Reaction: Toofani Tezi!
Is deal ka asar turant stock par dikha. Emcure ka share pehle Rs 1,769 ke intraday high tak gaya aur phir Rs 1,729.90 par close hua, jo ki ek record closing hai! Matlab 7.57% ka bhari jump aaya hai, aur volumes bhi zabardast the.
Emcure Ki Valuation Aur Pharma Sector Ka Outlook
Emcure Pharmaceuticals ki market cap lagbhag ₹32,700 Crore hai. Iska P/E ratio 34-47 ke aas paas hai, jo Nifty Pharma index ke average P/E 34.7 ke kareeb hai. Overall pharma sector bhi achha perform kar raha hai, FY26 mein 7-9% revenue growth expect hai, jismein domestic demand se 8-10% aur Europe se 10-12% growth aa rahi hai. US market mein thoda slowing dikh raha hai, bas 3-5% growth hi hai regulatory issues ke karan.
Aur Kahan Hui Deals?
Aisa nahi hai ki sirf Emcure mein deals hui. Accretion Pharmaceuticals mein bhi Unicorn Fund ne entry maari hai. Yeh company choti hai, market cap lagbhag ₹105 Crore hai aur stock 5% upper circuit laga gaya. Ek aur deal thi SG Finserve mein, jahan promoter group ne apni holding badhai hai. Is financial services firm ki market cap ₹3,600 Crore hai aur share Rs 565.75 par close hua.
Potential Risks Bhi Dekhein
Par bhai, har trade mein risk hota hai. Emcure mein bhi pehle volatility dekhi gayi hai, aur kabhi kabhi bain capital wale bhi discount par shares bechte rahe hain. Unka weight management drug Poviztra® ka price bhi reduce kiya gaya tha taaki zyada log use kar saken, jisse short-term profit par impact pad sakta hai. US market ke regulatory issues toh hain hi. SG Finserve ki ROE bhi bas 10.3% ke aas paas hai aur koi dividend nahi milta. Accretion jaisi choti companies mein P/E bhi fluctuate karta rehta hai.
Analysts Kya Keh Rahe Hain?
Waise analysts Emcure ko lekar kaafi positive hain. Kuch 6 analysts ne 'Strong Buy' rating di hai aur unka target price ₹1,780 se ₹1,795 tak hai, matlab abhi bhi 9% se zyada upside possible hai. Toh overall picture toh achha lag raha hai, bas market ke risks ko dhyan mein rakhna hoga.